Acromegaly is characterized by increased release of growth hormone and, consequently,
insulin-like growth factor I (IGF1), most often by a pituitary adenoma. Prolonged exposure to …

First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical
treatment of acromegaly, however the percentage of patients controlled with these drugs …

Abstract Purpose The phase 3 CHIASMA OPTIMAL trial (NCT03252353) evaluated efficacy
and safety of oral octreotide capsules (OOCs) in patients with acromegaly who previously …

Background Despite biochemically responding to injectable somatostatin receptor ligands
(iSRLs), many patients with acromegaly experience treatment burdens. We aimed to assess …

Context The somatostatin analogues octreotide LAR and lanreotide Autogel have been
evaluated for the treatment of acromegaly in numerous clinical trials, with considerable …

Gonadal steroids modulate the effects of GH, with oestrogens attenuating and androgens
augmenting GH action. Whether these divergent effects influence the clinical manifestation …

Somatostatin analogs, such as octreotide (OCT), lanreotide, and pasireotide, which function
as somatostatin receptor ligands (SRLs), are the main drugs used for the treatment of …

Context Pasireotide-LAR, a second-generation somatostatin receptor ligand (SRL), is
recommended for patients with acromegaly as second-line treatment. Its efficacy and safety …

Standard treatment for acromegaly focuses on the achievement of target absolute levels of
growth hormone (GH) and insulin-like growth factor (IGF-I). The appropriateness of these …

Acromegaly is a rare and severe disease caused by an increased and autonomous
secretion of growth hormone (GH), thus resulting in high circulating levels of insulin-like …